logo-loader
AIM:ONC

Oncimmune

Receive alerts
Market:
AIM
Market Cap:
£31.12 m
Price
49.00 GBX
Change
0.00%
52 weeks high
111.45
52 weeks low
30.00

In brief

Oncimmune's range of diagnostic tests profile the body’s immune response to detect evidence of the body’s natural response to cancer, which can detect cancer on average four years earlier than standard clinical diagnosis. 

Deep dive We explore the investor case for growth companies

Snapshot

  • EarlyCDT test met primary endpoint in lung cancer study
  • Has European CE mark approval for the EarlyCDT- Lung test
  • Deal with US firm for EarlyCDT